Guardant Health (GH) to Release Earnings on Wednesday

Guardant Health (NASDAQ:GH - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results after the market closes on Wednesday, April 30th. Analysts expect the company to announce earnings of ($0.57) per share and revenue of $189.91 million for the quarter. Guardant Health has set its FY 2025 guidance at EPS.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. On average, analysts expect Guardant Health to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Guardant Health Stock Performance

Shares of NASDAQ GH traded down $0.59 during trading on Monday, reaching $47.72. The stock had a trading volume of 532,011 shares, compared to its average volume of 2,138,567. The firm's 50 day moving average price is $43.37 and its two-hundred day moving average price is $37.42. The stock has a market cap of $5.89 billion, a PE ratio of -13.40 and a beta of 1.45. Guardant Health has a one year low of $17.52 and a one year high of $50.89.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Scotiabank boosted their target price on Guardant Health from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Monday, February 24th. Morgan Stanley boosted their price target on Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a report on Thursday, March 6th. Raymond James reiterated an "outperform" rating and set a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Stephens restated an "overweight" rating and issued a $55.00 price objective on shares of Guardant Health in a report on Wednesday, March 26th. Finally, JPMorgan Chase & Co. upped their price target on Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Twenty research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $49.00.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.